OvaScience completes enrollment in pilot trial of OvaPrime

OvaScience Inc. (NASDAQ:OVAS) completed enrollment of 70 patients with primary ovarian insufficiency or poor ovarian response in a pilot trial evaluating OvaPrime. Women will receive OvaPrime in 1 ovary, with the other ovary acting as a control.

The trial’s primary endpoint is safety. Secondary endpoints include hormone level change, development of new follicles, egg maturation, pre-implantation genetic screening and pregnancy. OvaScience expects interim data from the trial by year end...